$HUN

Huntsman Targets $300 Million in Synergies; $100 Million Tied to Chlorine Contracts

Huntsman expects 2026 EBITDA to improve by over $100M from 2025. The company targets $300M in synergies from its merger with Olin, expected to close in early 2027, and an additional $100M from chlorine contracts. Huntsman reported an $82M free cash flow inflow in Q3 and anticipates a substantial Q4 cash inflow.

Original reporting
Published Nov 4, 2026, 4:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 6:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Huntsman Targets $300 Million in Synergies; $100 Million Tied to Chlorine Contracts — source image
Decision brief

The 30-second read

$HUNBullishMed
01

Why it matters

The announced EBITDA improvement and synergy targets provide fresh guidance that could shift valuation.

02

Market read

New guidance and merger synergies are material for investors and may influence HUN's stock price ahead of 2026 earnings.

03

What to watch

Potential regulatory scrutiny of the Huntsman-Olin merger could delay or reduce expected benefits.

Relevance 7/10Novelty 7/10Timing: pre-2026 earnings guidance

Background

Huntsman Corp (HUN) is a U.S.-listed specialty chemicals company planning to merge with Olin Corp.

Company-level read

Ticker impact

$HUNBullishHigh confidence
Context

Huntsman disclosed expected 2026 EBITDA improvement of >$100M and $300M synergies from its pending merger with Olin.

Expected impact

potential upside as investors price in higher EBITDA and synergy benefits

Evidence & confidence

The disclosed numbers are new, material, and directly affect earnings expectations.

Market effects

Chemicals sector may see broader valuation lift as merger synergies become a benchmark.

U.S. chemicals market could benefit from perceived consolidation benefits.

Limited to industry peers; no broad macro impact.

Counterpoint

If integration costs exceed expectations, the synergy estimate could be overstated, pressuring the stock.

Key entities

  • Huntsman Corp

    Specialty chemicals producer reporting new guidance.

  • Olin Corp

    Merger partner of Huntsman.

Related articles

$HUNMed

Huntsman Q3 Earnings Call Highlights

Huntsman (HUN) reported Q3 earnings, noting seasonal slowing and higher raw-material costs in North American MDI markets. The company expects 2027 industry MDI growth to be flat to 2% and sees growth opportunities in advanced materials and automotive applications. Huntsman generated $82M in free cash flow in Q3 and anticipates substantial cash inflow in Q4. Europe remains challenging due to high energy costs, while China's market shows stability.

$HUNMed

Huntsman Corp (HUN) (Q3 2026) Earnings Call Highlights: $100 Million EBITDA Boost

Huntsman Corp (HUN) reported a $100M EBITDA boost in Q3 2026, with CEO Peter Huntsman expressing confidence in meeting $300M synergy targets from the Olin merger. He discussed market positioning, cost management, and growth expectations, including GDP-plus growth in Advanced Materials through 2027. The company expects to cover its dividend and capex with operating cash flow, despite minimal cash flow in the first nine months.

$HUNMedAI 8/10

Huntsman: Q3 Earnings Snapshot

Huntsman Corp. (HUN) reported a Q3 loss of $18M, or 10 cents per share, missing analyst expectations of 7 cents per share. Adjusted earnings were 4 cents per share. Revenue was $1.72B, exceeding forecasts of $1.6B.